logo

project details

A multicenter collaborative skin research group focusing on novel treatment for epidermolysis bullosa

Université Laval
3 Sites
ON, QC

Dr. Lucie Germain

Position: Member

Recessive dystrophic epidermolysis bullosa (RDEB) is a disease affecting the skin and mucosa. RDEB patients have fragile skin due to collagen 7 mutation. There is no cure for EB. The only option is to treat recurrent wounds with daily care and bandages. Patients experience pain and suffering.The LOEX/CHU de Québec-Université Laval, a leader in regenerative medicine aimsto find a treatment for RDEB. The therapy would be based on skin substitutes produced with patient’s cells corrected by gene therapy. The objective of the proposal is to bring together clinicians, researchers and patient partners from Québec, Ontario and British Columbia. This group will work together to prepare a multicenter clinical trial to apply laboratory discoveries to patients. The patient partners will participate to the study design (for example, cost, patient information and consent form). In addition, we aim to give information on EB research to the Canadian patient community. Ultimately, our goal is to develop a definitive treatment for RDEB with our new therapeutic approach. This rare disease impacts on the quality of life of patients and their families. Therefore, this new treatment, if proven successful, could change lives of Canadian patients by improving skin stability and preventing recurring wounds.

view our other projects